These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22515609)

  • 1. The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy.
    Justenhoven C; Obazee O; Brauch H
    Pharmacogenomics; 2012 Apr; 13(6):659-75. PubMed ID: 22515609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hormone replacement therapy and cancer of the breast. 1. Does replacement therapy increase the risk of cancer of the breast?].
    Ayres de Campos D; Barros H; Martinez de Oliveira J
    Acta Med Port; 1997 Oct; 10(10):697-703. PubMed ID: 9477595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex steroid hormones and breast cancer: is there a link with oral contraceptives and hormone replacement therapy?
    Khoo SK; Chick P
    Med J Aust; 1992 Jan; 156(2):124-32. PubMed ID: 1736053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone replacement therapy in breast cancer survivors.
    Xydakis AM; Sakkas EG; Mastorakos G
    Ann N Y Acad Sci; 2006 Dec; 1092():349-60. PubMed ID: 17308160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen metabolism genotypes, use of long-term hormone replacement therapy and risk of postmenopausal breast cancer.
    Cerne JZ; Novakovic S; Frkovic-Grazio S; Pohar-Perme M; Stegel V; Gersak K
    Oncol Rep; 2011 Aug; 26(2):479-85. PubMed ID: 21567099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Controversy between estrogen replacement therapy and risk of breast cancer in menopause].
    Zárate A
    Gac Med Mex; 2002; 138(1):105-7. PubMed ID: 11885123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Stramba-Badiale M
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):303-9. PubMed ID: 19430340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risks and benefits of hormone replacement therapy.
    Boyd ME
    Can J Surg; 1995 Oct; 38(5):415-9. PubMed ID: 7553464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of HRT and the subsequent risk of cancer.
    Beral V; Banks E; Reeves G; Appleby P
    J Epidemiol Biostat; 1999; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone replacement therapy in women with a history of breast cancer.
    Ylikorkala O; Metsä-Heikkilä M
    Gynecol Endocrinol; 2002 Dec; 16(6):469-78. PubMed ID: 12626034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone replacement therapy in breast cancer patients and survivors.
    Del Priore G; Hatami M
    Curr Womens Health Rep; 2003 Apr; 3(2):165-9. PubMed ID: 12628087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
    L'Hermite M
    Climacteric; 2013 Aug; 16 Suppl 1():44-53. PubMed ID: 23848491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Asian Menopause Survey: knowledge, perceptions, hormone treatment and sexual function.
    Huang KE; Xu L; I NN; Jaisamrarn U
    Maturitas; 2010 Mar; 65(3):276-83. PubMed ID: 20018469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
    Skouby SO; Al-Azzawi F; Barlow D; Calaf-Alsina Erdogan Ertüngealp J; Gompel A; Graziottin A; Hudita D; Pines A; Rozenberg S; Samsioe G; Stevenson JC;
    Maturitas; 2005 May; 51(1):8-14. PubMed ID: 15883103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and management of the hormone replacement therapy (HRT) candidate.
    Hillard T
    Int J Fertil Womens Med; 1997; 42 Suppl 2():347-64. PubMed ID: 9397383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
    Dew JE; Wren BG; Eden JA
    Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.